Boston Scientific Co. (BSX) EVP Kevin J. Ballinger Sells 28,864 Shares of Stock

Boston Scientific Co. (NYSE:BSX) EVP Kevin J. Ballinger sold 28,864 shares of the business’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $26.14, for a total value of $754,504.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Boston Scientific Co. (NYSE:BSX) traded up 1.03% during midday trading on Friday, reaching $26.41. The company’s stock had a trading volume of 7,924,635 shares. The stock has a market capitalization of $36.17 billion, a PE ratio of 84.65 and a beta of 1.06. Boston Scientific Co. has a 12 month low of $19.67 and a 12 month high of $26.76. The stock’s 50 day moving average is $25.58 and its 200 day moving average is $23.71.

Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, April 27th. The medical equipment provider reported $0.29 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.30 by $0.01. Boston Scientific had a return on equity of 23.70% and a net margin of 4.14%. The firm had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.08 billion. During the same period in the previous year, the firm earned $0.28 EPS. Boston Scientific’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, analysts forecast that Boston Scientific Co. will post $1.25 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

ILLEGAL ACTIVITY WARNING: “Boston Scientific Co. (BSX) EVP Kevin J. Ballinger Sells 28,864 Shares of Stock” was reported by Mideast Time and is the property of of Mideast Time. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.mideasttime.com/boston-scientific-co-bsx-evp-kevin-j-ballinger-sells-28864-shares-of-stock/1708859.html.

Several equities analysts have issued reports on the company. Goldman Sachs Group Inc assumed coverage on Boston Scientific in a research report on Tuesday. They set a “neutral” rating and a $28.00 target price on the stock. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “hold” rating in a research report on Monday, May 1st. Stifel Nicolaus boosted their target price on Boston Scientific from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Cowen and Company boosted their target price on Boston Scientific from $29.00 to $31.00 and gave the stock an “outperform” rating in a research report on Friday, April 28th. Finally, Evercore ISI boosted their target price on Boston Scientific from $26.50 to $28.50 and gave the stock an “outperform” rating in a research report on Friday, April 28th. Six research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $27.83.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Synovus Financial Corp acquired a new position in Boston Scientific during the third quarter valued at about $102,000. Quadrant Capital Group LLC raised its position in Boston Scientific by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock valued at $122,000 after buying an additional 487 shares during the period. Bronfman E.L. Rothschild L.P. raised its position in Boston Scientific by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 338 shares during the period. Guardian Life Insurance Co. of America raised its position in Boston Scientific by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 49 shares during the period. Finally, JNBA Financial Advisors raised its position in Boston Scientific by 467.9% in the fourth quarter. JNBA Financial Advisors now owns 7,298 shares of the medical equipment provider’s stock valued at $158,000 after buying an additional 6,013 shares during the period. Hedge funds and other institutional investors own 91.70% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

12 Month Chart for NYSE:BSX

Receive News & Ratings for Boston Scientific Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Co. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.